IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10683282 B1

PDFFull Text
Date of Patent:
Jun. 16, 2020

Filed:

Mar. 22, 2019

Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities

Applicant:

Korea Institute of Science and Technology, Seoul, KR;

Inventors:

So Ha Lee, Seoul, KR;

Kyung Ho Yoo, Seoul, KR;

Eun Joo Roh, Seoul, KR;

Tae Bo Sim, Seoul, KR;

Tae Young Kim, Seoul, KR;

Jae Ho Kim, Seoul, KR;

Assignee:

KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, Seoul, KR;

Attorney:

Goldilocks Zone IP Law

Primary Examiner:

Alexander R Pagano

Assistant Examiner:

Ebenezer O Sackey

Int. Cl.
CPC ...
C07D 405/14 (2006.01); C07D 405/12 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 239/48 (2006.01); A61P 35/00 (2006.01); A61P 25/28 (2006.01); A61P 37/02 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
C07D 405/14 (2013.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); C07D 239/48 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01);
Abstract

Disclosed are a novel pyrimidine derivative compound, a pharmaceutically acceptable salt thereof, a method for preparing the compound and a pharmaceutical use of the compound as an anticancer agent or a therapeutic agent for degenerative brain diseases. Specifically, the novel pyrimidine derivative compound has excellent inhibitory activities against kinase enzymes such as ARK5/NUAK1, ACK1, FLT3, JAK1, JAK2 and JAK2 (V617F) and thus is useful for treating and preventing leukemia, ovarian cancer, breast cancer, non-small cell carcinoma, colorectal cancer, glioma, and brain protein abnormalities such as Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia, that is, degenerative diseases caused by Tau deposition.

Find Patent Forward Citations

Loading…